vs
American Bitcoin Corp.（ABTC）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是American Bitcoin Corp.的1.9倍（$219.9M vs $118.0M），American Bitcoin Corp.同比增速更快（151.5% vs 2.0%），过去两年American Bitcoin Corp.的营收复合增速更高（296.9% vs 8.0%）
美国比特币公司专注于比特币相关业务领域。比特币是首个去中心化加密货币，由化名为中本聪的匿名人士于2008年发布白皮书后诞生，2009年随着开源代码上线正式投入使用，问世以来对全球金融与数字货币领域都产生了极为深远的影响。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
ABTC vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.9倍
$118.0M
营收增速更快
ABTC
高出149.5%
2.0%
两年增速更快
ABTC
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $118.0M | $219.9M |
| 净利润 | — | $-2.2M |
| 毛利率 | 49.1% | 71.1% |
| 营业利润率 | -192.8% | 0.2% |
| 净利率 | — | -1.0% |
| 营收同比 | 151.5% | 2.0% |
| 净利润同比 | — | 92.4% |
| 每股收益（稀释后） | $-0.07 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABTCOFIX
| Q4 25 | $118.0M | $219.9M | ||
| Q3 25 | $64.2M | $205.6M | ||
| Q2 25 | $1.4M | $203.1M | ||
| Q1 25 | $1.6M | $193.6M | ||
| Q4 24 | $46.9M | $215.7M | ||
| Q3 24 | $11.6M | $196.6M | ||
| Q2 24 | $5.5M | $198.6M | ||
| Q1 24 | $7.5M | $188.6M |
净利润ABTCOFIX
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $3.5M | $-22.8M | ||
| Q2 25 | $3.4M | $-14.1M | ||
| Q1 25 | $-100.6M | $-53.1M | ||
| Q4 24 | — | $-29.1M | ||
| Q3 24 | $-576.0K | $-27.4M | ||
| Q2 24 | $-61.1M | $-33.4M | ||
| Q1 24 | $230.4M | $-36.0M |
毛利率ABTCOFIX
| Q4 25 | 49.1% | 71.1% | ||
| Q3 25 | 56.0% | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | 57.9% | 69.0% | ||
| Q3 24 | 4.2% | 68.7% | ||
| Q2 24 | 31.0% | 67.8% | ||
| Q1 24 | 35.4% | 67.5% |
营业利润率ABTCOFIX
| Q4 25 | -192.8% | 0.2% | ||
| Q3 25 | 11.2% | -8.3% | ||
| Q2 25 | -162.1% | -7.9% | ||
| Q1 25 | -350.8% | -25.2% | ||
| Q4 24 | — | -5.3% | ||
| Q3 24 | -87.8% | -9.6% | ||
| Q2 24 | -106.4% | -12.5% | ||
| Q1 24 | -20.8% | -15.6% |
净利率ABTCOFIX
| Q4 25 | — | -1.0% | ||
| Q3 25 | 5.4% | -11.1% | ||
| Q2 25 | 249.2% | -6.9% | ||
| Q1 25 | -6458.5% | -27.4% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | -5.0% | -13.9% | ||
| Q2 24 | -1107.2% | -16.8% | ||
| Q1 24 | 3076.2% | -19.1% |
每股收益（稀释后）ABTCOFIX
| Q4 25 | $-0.07 | $-0.05 | ||
| Q3 25 | $0.06 | $-0.57 | ||
| Q2 25 | $-0.07 | $-0.36 | ||
| Q1 25 | $-0.09 | $-1.35 | ||
| Q4 24 | $1.10 | $-0.76 | ||
| Q3 24 | $-0.15 | $-0.71 | ||
| Q2 24 | $-0.10 | $-0.88 | ||
| Q1 24 | $-0.36 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $665.8M | $450.0M |
| 总资产 | $1.2B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ABTCOFIX
| Q4 25 | — | $82.0M | ||
| Q3 25 | — | $62.9M | ||
| Q2 25 | $750.0K | $65.6M | ||
| Q1 25 | $367.0K | $58.0M | ||
| Q4 24 | $850.0K | $83.2M | ||
| Q3 24 | $478.0K | $30.1M | ||
| Q2 24 | $1.4M | $26.4M | ||
| Q1 24 | $1.9M | $27.0M |
总债务ABTCOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益ABTCOFIX
| Q4 25 | $665.8M | $450.0M | ||
| Q3 25 | $575.5M | $442.5M | ||
| Q2 25 | $339.7M | $458.3M | ||
| Q1 25 | $115.8M | $458.3M | ||
| Q4 24 | $1.0B | $503.1M | ||
| Q3 24 | $697.5M | $525.9M | ||
| Q2 24 | $614.3M | $546.0M | ||
| Q1 24 | $696.8M | $570.3M |
总资产ABTCOFIX
| Q4 25 | $1.2B | $850.6M | ||
| Q3 25 | $1.2B | $832.6M | ||
| Q2 25 | $6.2M | $837.2M | ||
| Q1 25 | $9.0M | $823.1M | ||
| Q4 24 | $1.1B | $893.3M | ||
| Q3 24 | $7.5M | $867.9M | ||
| Q2 24 | $11.4M | $882.0M | ||
| Q1 24 | $17.8M | $906.0M |
负债/权益比ABTCOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-79.6M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流ABTCOFIX
| Q4 25 | $-79.6M | $27.7M | ||
| Q3 25 | $-39.0M | $12.4M | ||
| Q2 25 | $-879.0K | $11.6M | ||
| Q1 25 | $-3.2M | $-18.4M | ||
| Q4 24 | $-54.0M | $23.7M | ||
| Q3 24 | $-76.8M | $11.7M | ||
| Q2 24 | $201.0K | $9.0M | ||
| Q1 24 | $-983.0K | $-18.6M |
自由现金流ABTCOFIX
| Q4 25 | — | $16.8M | ||
| Q3 25 | — | $2.5M | ||
| Q2 25 | $-1.4M | $4.5M | ||
| Q1 25 | — | $-25.1M | ||
| Q4 24 | $-60.6M | $15.2M | ||
| Q3 24 | $-79.3M | $6.3M | ||
| Q2 24 | $-874.0K | $-360.0K | ||
| Q1 24 | — | $-29.1M |
自由现金流率ABTCOFIX
| Q4 25 | — | 7.6% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | -104.4% | 2.2% | ||
| Q1 25 | — | -13.0% | ||
| Q4 24 | -129.2% | 7.0% | ||
| Q3 24 | -683.2% | 3.2% | ||
| Q2 24 | -15.8% | -0.2% | ||
| Q1 24 | — | -15.4% |
资本支出强度ABTCOFIX
| Q4 25 | — | 4.9% | ||
| Q3 25 | — | 4.8% | ||
| Q2 25 | 40.5% | 3.5% | ||
| Q1 25 | — | 3.5% | ||
| Q4 24 | 14.1% | 4.0% | ||
| Q3 24 | 21.6% | 2.7% | ||
| Q2 24 | 19.5% | 4.7% | ||
| Q1 24 | — | 5.6% |
现金转化率ABTCOFIX
| Q4 25 | — | — | ||
| Q3 25 | -11.21× | — | ||
| Q2 25 | -0.26× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.00× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABTC
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
